ALKEM.NS Balance Sheet
Alkem Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹20.65 Bn | ₹21.61 Bn | ₹20.64 Bn | ₹26.95 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹3.10 Bn | ₹1.48 Bn | ₹4.77 Bn | ₹1.38 Bn | CapitalWorkInProgress |
| Goodwill | ₹4.13 Bn | ₹4.17 Bn | ₹4.23 Bn | ₹5.24 Bn | Goodwill |
| Other Intangible Assets | ₹2.04 Bn | ₹2.95 Bn | ₹3.65 Bn | ₹6.52 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹3.05 Bn | ₹3.35 Bn | ₹9.43 Bn | ₹11.31 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹1.10 Bn | ₹1.62 Bn | ₹1.88 Bn | ₹3.43 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹50.27 Bn | ₹51.63 Bn | ₹67.45 Bn | ₹86.62 Bn | NoncurrentAssets |
| Inventories | ₹26.08 Bn | ₹26.61 Bn | ₹29.22 Bn | ₹33.33 Bn | Inventories |
| Trade Receivables | ₹21.32 Bn | ₹22.53 Bn | ₹24.66 Bn | ₹29.79 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹2.74 Bn | ₹4.55 Bn | ₹3.04 Bn | ₹2.48 Bn | CashAndCashEquivalents |
| Current Investments | ₹3.17 Bn | ₹1.49 Bn | ₹9.02 Bn | ₹7.37 Bn | CurrentInvestments |
| Other Current Assets | ₹7.36 Bn | ₹8.30 Bn | ₹8.33 Bn | ₹8.99 Bn | OtherCurrentAssets |
| Total Current Assets | ₹86.06 Bn | ₹104.12 Bn | ₹108.11 Bn | ₹122.11 Bn | CurrentAssets |
| Total Assets | ₹137.57 Bn | ₹155.75 Bn | ₹176.91 Bn | ₹208.73 Bn | Assets |
| Equity Share Capital | ₹0.24 Bn | ₹0.24 Bn | ₹0.24 Bn | ₹0.24 Bn | EquityShareCapital |
| Other Equity | ₹90.21 Bn | ₹102.88 Bn | ₹119.61 Bn | ₹137.96 Bn | OtherEquity |
| Equity Attributable to Owners | ₹90.45 Bn | ₹103.12 Bn | ₹119.85 Bn | ₹138.20 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹3.90 Bn | ₹4.02 Bn | ₹4.49 Bn | ₹5.29 Bn | NonControllingInterest |
| Total Equity | ₹94.35 Bn | ₹107.14 Bn | ₹124.34 Bn | ₹143.49 Bn | Equity |
| Long-term Borrowings | ₹0.70 Bn | ₹0.40 Bn | ₹3.11 Bn | ₹4.92 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹6.14 Bn | ₹8.66 Bn | ₹12.92 Bn | ₹17.41 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹13.26 Bn | ₹11.74 Bn | ₹7.52 Bn | ₹11.31 Bn | BorrowingsCurrent |
| Trade Payables | ₹11.65 Bn | ₹17.48 Bn | ₹18.39 Bn | ₹22.44 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹1.87 Bn | ₹2.30 Bn | ₹3.06 Bn | ₹3.19 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹37.07 Bn | ₹39.95 Bn | ₹39.59 Bn | ₹47.83 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹137.57 Bn | ₹155.75 Bn | ₹176.91 Bn | ₹208.73 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from ALKEM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).